An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD

PHASE4CompletedINTERVENTIONAL
Enrollment

246

Participants

Timeline

Start Date

March 22, 2023

Primary Completion Date

May 2, 2024

Study Completion Date

May 2, 2024

Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
DRUG

Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)

Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)

OTHER

placebo

matching placebo

Trial Locations (20)

30030

CenExel IResearch, LLC - Decatur, Decatur

30339

Sky Clinical Research Network Group P.C., Atlanta

31405

CenExel iResearch, LLC, Savannah

32256

Clinical Neuroscience Solutions - Jacksonville, Jacksonville

32751

Accel Research Sites - Maitland, Maitland

32801

CNS Healthcare - Orlando, Orlando

33166

South Florida Research Phase I-IV INC, Miami Springs

33803

Accel Research Sites - Lakeland, Lakeland

38119

Clinical Neuroscience Solutions--Memphis, Memphis

68526

Alivation Research, LLC, Lincoln

70115

DelRicht Research - Touro Medical Center, New Orleans

72211

Preferred Research Partners (PRP), Little Rock

75093

Boeson Research, Missoula

AIM Trials, Plano

77401

Houston Clinical Trials, Bellaire

78229

Flourish Research, San Antonio

80112

IMMUNOe International Research Center, Centennial

St Charles Psychiatric Associates & Midwest Research Group, Saint Charles

89128

Center for Psychiatry and Behavioral Medicine Inc, Las Vegas

92805

Advanced Research Center (ARC), Anaheim

Sponsors
All Listed Sponsors
collaborator

Premier Research Group plc

UNKNOWN

collaborator

Prometrika, LLC

INDUSTRY

collaborator

Almac

INDUSTRY

lead

Corium, Inc.

INDUSTRY

NCT05685732 - An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD | Biotech Hunter | Biotech Hunter